Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow SOLV
Solventum Corporation (SOLV) Revenue
Solventum Corporation's revenue for fiscal 2025 was $8.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $8.3B. Revenue has risen for 3 consecutive fiscal years. Solventum Corporation ranks 6th of 50 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $8.3B | 0.86% |
| FY2024 | $8.3B | 0.70% |
| FY2023 | $8.2B | 0.82% |
| FY2022 | $8.1B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $2.2B | 10.06% |
| Mar 2026 | $2.0B | 0.45% |
| Dec 2025 | $2.0B | (4.68%) |
| Sep 2025 | $2.1B | (3.01%) |
| 10 more quarters | Free account |
Revenue against peers
| Company | Revenue |
|---|---|
| BAX Baxter International Inc. compare | $11.5B |
| ALC Alcon compare | $10.9B |
| SOLV Solventum Corporation | $8.3B |
| AVTR Avantor, Inc. compare | $6.6B |
| COO The Cooper Companies, Inc. compare | $4.2B |
| ALGN Align Technology, Inc. compare | $4.1B |
| ATR AptarGroup, Inc. compare | $3.9B |
| WST West Pharmaceutical Services, Inc. compare | $3.3B |
| RGEN Repligen Corporation compare | $785.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SOLV
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement